Cargando…
CDC50A might be a novel biomarker of epithelial ovarian cancer-initiating cells
BACKGROUND: The aim of this work was to screen and validate biomarkers of ovarian cancer-initiating cells to detect the mechanisms of recurrence of epithelial ovarian cancer (EOC). METHODS: Stably labelled the amino acid in side population (SP) cells of epithelial ovarian cancer which were rich in c...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389740/ https://www.ncbi.nlm.nih.gov/pubmed/35982417 http://dx.doi.org/10.1186/s12885-022-09953-y |
_version_ | 1784770523576664064 |
---|---|
author | Yin, Jie Wen, Yiping Zeng, Jing Zhang, Yanyan Chen, Jiayu Zhang, Yanmei Han, Tiantian Li, Xiaoying Huang, Hong Cai, Yan Jin, Ying Li, Yan Guo, Wei Pan, Lingya |
author_facet | Yin, Jie Wen, Yiping Zeng, Jing Zhang, Yanyan Chen, Jiayu Zhang, Yanmei Han, Tiantian Li, Xiaoying Huang, Hong Cai, Yan Jin, Ying Li, Yan Guo, Wei Pan, Lingya |
author_sort | Yin, Jie |
collection | PubMed |
description | BACKGROUND: The aim of this work was to screen and validate biomarkers of ovarian cancer-initiating cells to detect the mechanisms of recurrence of epithelial ovarian cancer (EOC). METHODS: Stably labelled the amino acid in side population (SP) cells of epithelial ovarian cancer which were rich in cancer-initiating cells and non-SP cells with isotope in culture and differentially expressed cellular membrane proteins in SP cells were identified through proteomics technology. The new candidate biomarker was screened and validated through RT-PCR and western blot. Both in cell lines and primary EOC, cancer-initiating biofunctions of CDC50A positive cells were validated. Moreover, the characteristics of mesenchymal transition (EMT) was also detected and the correlation between the biomarker and clinical prognosis was observed. RESULTS: Through proteomics technology, candidate protein CDC50A was screened, and its significantly differential expression in SP cells was validated. CDC50A-positive cells from cell lines and primary ovarian cancer tissues were validated to show characteristics of cancer-initiating cells both in vitro and in vivo, including sphere-forming, self-renewal, differentiation, tumor metastasis and tumorigenicity in mice. The relationship between CDC50A-positive cells from primary tissues and tumour metastasis was confirmed based on their mesenchymal transition characteristics. Among 16 high-grade ovarian serous cancer patients, a high ratio of CDC50A-positive cells in primary tumours was correlated with a shorter platinum-free interval (p = 0.031, HR 0.260, 95% CI 0.77 ~ 0.885). CONCLUSION: CDC50A could be used to screen ovarian cancer-initiating cells and might be a new target to resolve tumour development in EOC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09953-y. |
format | Online Article Text |
id | pubmed-9389740 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93897402022-08-20 CDC50A might be a novel biomarker of epithelial ovarian cancer-initiating cells Yin, Jie Wen, Yiping Zeng, Jing Zhang, Yanyan Chen, Jiayu Zhang, Yanmei Han, Tiantian Li, Xiaoying Huang, Hong Cai, Yan Jin, Ying Li, Yan Guo, Wei Pan, Lingya BMC Cancer Research BACKGROUND: The aim of this work was to screen and validate biomarkers of ovarian cancer-initiating cells to detect the mechanisms of recurrence of epithelial ovarian cancer (EOC). METHODS: Stably labelled the amino acid in side population (SP) cells of epithelial ovarian cancer which were rich in cancer-initiating cells and non-SP cells with isotope in culture and differentially expressed cellular membrane proteins in SP cells were identified through proteomics technology. The new candidate biomarker was screened and validated through RT-PCR and western blot. Both in cell lines and primary EOC, cancer-initiating biofunctions of CDC50A positive cells were validated. Moreover, the characteristics of mesenchymal transition (EMT) was also detected and the correlation between the biomarker and clinical prognosis was observed. RESULTS: Through proteomics technology, candidate protein CDC50A was screened, and its significantly differential expression in SP cells was validated. CDC50A-positive cells from cell lines and primary ovarian cancer tissues were validated to show characteristics of cancer-initiating cells both in vitro and in vivo, including sphere-forming, self-renewal, differentiation, tumor metastasis and tumorigenicity in mice. The relationship between CDC50A-positive cells from primary tissues and tumour metastasis was confirmed based on their mesenchymal transition characteristics. Among 16 high-grade ovarian serous cancer patients, a high ratio of CDC50A-positive cells in primary tumours was correlated with a shorter platinum-free interval (p = 0.031, HR 0.260, 95% CI 0.77 ~ 0.885). CONCLUSION: CDC50A could be used to screen ovarian cancer-initiating cells and might be a new target to resolve tumour development in EOC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09953-y. BioMed Central 2022-08-19 /pmc/articles/PMC9389740/ /pubmed/35982417 http://dx.doi.org/10.1186/s12885-022-09953-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yin, Jie Wen, Yiping Zeng, Jing Zhang, Yanyan Chen, Jiayu Zhang, Yanmei Han, Tiantian Li, Xiaoying Huang, Hong Cai, Yan Jin, Ying Li, Yan Guo, Wei Pan, Lingya CDC50A might be a novel biomarker of epithelial ovarian cancer-initiating cells |
title | CDC50A might be a novel biomarker of epithelial ovarian cancer-initiating cells |
title_full | CDC50A might be a novel biomarker of epithelial ovarian cancer-initiating cells |
title_fullStr | CDC50A might be a novel biomarker of epithelial ovarian cancer-initiating cells |
title_full_unstemmed | CDC50A might be a novel biomarker of epithelial ovarian cancer-initiating cells |
title_short | CDC50A might be a novel biomarker of epithelial ovarian cancer-initiating cells |
title_sort | cdc50a might be a novel biomarker of epithelial ovarian cancer-initiating cells |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389740/ https://www.ncbi.nlm.nih.gov/pubmed/35982417 http://dx.doi.org/10.1186/s12885-022-09953-y |
work_keys_str_mv | AT yinjie cdc50amightbeanovelbiomarkerofepithelialovariancancerinitiatingcells AT wenyiping cdc50amightbeanovelbiomarkerofepithelialovariancancerinitiatingcells AT zengjing cdc50amightbeanovelbiomarkerofepithelialovariancancerinitiatingcells AT zhangyanyan cdc50amightbeanovelbiomarkerofepithelialovariancancerinitiatingcells AT chenjiayu cdc50amightbeanovelbiomarkerofepithelialovariancancerinitiatingcells AT zhangyanmei cdc50amightbeanovelbiomarkerofepithelialovariancancerinitiatingcells AT hantiantian cdc50amightbeanovelbiomarkerofepithelialovariancancerinitiatingcells AT lixiaoying cdc50amightbeanovelbiomarkerofepithelialovariancancerinitiatingcells AT huanghong cdc50amightbeanovelbiomarkerofepithelialovariancancerinitiatingcells AT caiyan cdc50amightbeanovelbiomarkerofepithelialovariancancerinitiatingcells AT jinying cdc50amightbeanovelbiomarkerofepithelialovariancancerinitiatingcells AT liyan cdc50amightbeanovelbiomarkerofepithelialovariancancerinitiatingcells AT guowei cdc50amightbeanovelbiomarkerofepithelialovariancancerinitiatingcells AT panlingya cdc50amightbeanovelbiomarkerofepithelialovariancancerinitiatingcells |